Share on StockTwits

Shares of Curis (NASDAQ:CRIS) were the recipient of a large increase in short interest in June. As of June 30th, there was short interest totalling 8,275,495 shares, an increase of 23.7% from the June 13th total of 6,692,521 shares, American Banking & Market News reports. Based on an average trading volume of 2,469,249 shares, the short-interest ratio is presently 3.4 days. Approximately 9.9% of the shares of the stock are short sold.

CRIS has been the subject of a number of recent research reports. Analysts at Zacks upgraded shares of Curis from a “neutral” rating to an “outperform” rating in a research note on Wednesday, July 9th. They now have a $2.10 price target on the stock. Analysts at Oppenheimer cut their price target on shares of Curis from $4.50 to $3.00 in a research note on Friday, May 9th. They now have an “outperform” rating on the stock. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $4.92.

Curis (NASDAQ:CRIS) opened at 1.76 on Wednesday. Curis has a 1-year low of $1.60 and a 1-year high of $4.74. The stock’s 50-day moving average is $1.74 and its 200-day moving average is $2.46. The company’s market cap is $151.3 million.

Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.06). The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.88 million. During the same quarter last year, the company posted ($0.06) earnings per share. Curis’s revenue was up 42.2% compared to the same quarter last year. Analysts expect that Curis will post $-0.21 EPS for the current fiscal year.

Curis, Inc is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.